Piper Sandler analyst Jason Bednar lowered the firm’s price target on Sotera Health to $13 from $15 and keeps a Neutral rating on the shares ahead of quarterly results. The firm notes that policy and broad economic uncertainty has seemingly created opportunities for investors to do value shopping, with Becton Dickinson (BDX) and Sotera Health (SHC) looking best positioned to respond favorably to upcoming reports when considering current sentiment/positioning.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SHC:
- Sotera Health price target lowered to $12 from $16 at Barclays
- Sotera Health Settles Ethylene Oxide Claims for $30.9M
- Sotera’s Nelson Labs launches rapid sterility testing to expedite results
- Sotera Health price target lowered to $16 from $17 at Barclays
- Sotera Health Reports 2024 Earnings and 2025 Outlook